Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 6/20 | 0.42 |
| ▸ | HTR2C | P28335 | 6/20 | 0.42 |
| ▸ | HTR2B | P41595 | 4/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.38 |
| ▸ | KMO | O15229 | 8/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30861000 | 1.00 | CYP1A2 (0.43) | CYP1A2HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL7571403 | 0.84 | CYP1A2 (0.63) | CYP1A2HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL23987082 | 0.84 | HTR2A (0.42) | CYP1A2HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL13607554 | 0.81 | KMO (0.55) | CYP1A2HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL30174529 | 0.78 | CYP1A2 (0.41) | CYP1A2HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL24337914 | 0.78 | CYP1A2 (0.41) | CYP1A2HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL217944 | 0.78 | HTR2A (0.45) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL31039602 | 0.78 | HTR2A (0.45) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL31236306 | 0.76 | CYP1A2 (0.70) | CYP1A2ADRA2AKMO | |
| SCHEMBL4319982 | 0.76 | CYP1A2 (0.70) | CYP1A2ADRA2AKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024073073-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20040039019-A1 | Selected anthranilaminde pyridinamides and their use as pharmaceutical agents | SCHERING AG (DE) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039019-A1 | Selected anthranilaminde pyridinamides and their use as pharmaceutical agents | KDR, FLT1, FLT4 | CYP1A2 37/4885HTR2A 475/4885HTR2C 519/4885 |
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | LRRK2, MAP3K20, MAP3K5 | CYP1A2 4674/4885HTR2A 2485/4885HTR2C 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.